CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Basal Insulin Formulations for the Management of Type 2 Diabetes

Last updated: March 11, 2021
Project Number: RB1548-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the comparative risk of hypoglycemia in patients receiving various basal insulin formulations for the management of type 2 diabetes?

Key Message

Four systematic reviews (2 with meta-analyses and 2 with network meta-analyses), 22 randomized controlled trials, and 10 non-randomized studies were identified regarding the comparative risk of hypoglycemia in patients receiving various basal insulin formulations for the management of type 2 diabetes.